nejm glp 1 on X: "GLP-1 receptor agonists can reduce the risk of adverse cardiovascular events in pts with diabetes. Whether the GLP-1 receptor agonist semaglutide can also reduce cardiovascular risk in pts with NEJM trial data on orforglipron

A fasting glucose crossing 126 mg/dL on two separate measurements meets the ADA diagnostic threshold for diabetes [6] and requires either dose reduction, therapy discontinuation, or initiation of glucose-lowering medication

Recent research suggests that GLP-1 drugs may have promise in the treatment of cardiovascular disease, neurodegenerative disorders, and drug and alcohol addiction, among others

Moreover, the brand requires further clinical evidence and research to prove these claims

Studies have shown benefits in both hypothyroidism and hyperthyroidism

In contrast to their beneficial effects, these enzymes also participate in formation of reactive intermediates of various compounds